ONWARD Medical Reports Strong Q1 2026 Growth, Raises €40M
Event summary
- ONWARD Medical supplied 70 ARC-EX® Systems in Q1 2026, with availability in over 100 clinics across the US and Europe.
- First participant enrolled and first successful implant in the Empower BP pivotal study for ARC-IM® System.
- Company reported EUR 2.0 million in revenue and raised EUR 40 million in equity capital in April 2026.
- ARC-BCI® Therapy successfully administered to two additional individuals with spinal cord injuries.
The big picture
ONWARD Medical's strong Q1 2026 performance underscores the growing demand for its neurotechnology solutions in the spinal cord injury market. The company's ability to secure significant equity funding highlights investor confidence in its pipeline and commercial traction. The strategic focus on expanding clinical trials and home-use applications positions ONWARD Medical to capitalize on the increasing need for innovative therapies in neurorehabilitation.
What we're watching
- Commercial Expansion
- How the rapid adoption of ARC-EX in clinics and homes will impact revenue growth and market penetration.
- Clinical Progress
- Whether the Empower BP study will successfully demonstrate the safety and effectiveness of ARC-IM, accelerating regulatory approval.
- Financial Runway
- The pace at which ONWARD Medical will deploy its EUR 40 million raise to advance commercial and clinical initiatives.
Related topics